#Innovations in CTLA-4 Therapies | Explore Tumblr Posts and Blogs

amolbhanushali · 5 months

Text

The Fight Against Lung Cancer: Advances in Treatment and Prognosis

Lung cancer remains one of the most devastating and deadly forms of cancer, accounting for a significant number of cancer-related deaths worldwide. However, in recent years, the landscape of lung cancer treatment has undergone a remarkable transformation, with advancements in various therapeutic approaches offering renewed hope for patients. That’s why patients always want the best thoracic surgeon for lung cancer.

From the emergence of targeted therapies that leverage precision medicine to the game-changing impact of immunotherapy, the fight against lung cancer has seen a surge of innovative solutions. Coupled with improvements in early detection and a growing emphasis on palliative care, these advancements have the potential to significantly improve prognosis and quality of life for those affected by this disease. This article will explore the key developments in lung cancer treatment and their implications for the future of patient care.

Targeted Therapies: Precision Medicine Approach

The most frequent type of lung cancer, non-small cell lung cancer (NSCLC), has never been treated the same way because of the development of tailored medicines. Dr. Amol Bhanushali - thoracic and chest surgeon is one of the best options for this part. By targeting specific genetic mutations or molecular pathways, these therapies have demonstrated improved outcomes and better-tolerated side effects compared to traditional chemotherapy.

Immunotherapy: Harnessing the Body's Immune System

Immunotherapy has become a game-changer in the treatment of lung cancer from the best thoracic surgeon for lung cancer. Particularly for advanced-stage NSCLC. Drugs that target immune checkpoint inhibitors, such as PD-1 and CTLA-4, have shown remarkable success in enhancing the body's immune response against cancer cells, leading to improved survival rates.

Combination Therapies: Synergistic Approaches

Recognizing the complexity of lung cancer, researchers have explored the potential of combining different treatment modalities, such as targeted therapies and immunotherapy. These combination approaches have demonstrated enhanced efficacy, often leading to better outcomes for patients with advanced-stage disease.

Advancements in Early Diagnosis

Early detection of lung cancer is crucial for improving prognosis, as it allows for more effective treatment options. Advancements in imaging techniques, such as low-dose computed tomography (CT) screening, have shown promise in identifying lung cancer at earlier, more treatable stages.

Improved Palliative Care and Quality of Life

Alongside advancements in curative treatments, there has been a growing emphasis on improving palliative care and quality of life for lung cancer patients. Supportive care measures, including pain management, symptom control, and psychosocial support, have become integral components of comprehensive lung cancer care.

Challenges and Future Directions

While significant progress has been made, challenges remain in the fight against lung cancer. Addressing drug resistance, identifying new therapeutic targets, and expanding access to innovative treatments are some of the key areas that require ongoing research and collaboration.

The fight against lung cancer when you have the best thoracic surgeon for lung cancer has seen remarkable advancements in recent years, with targeted therapies, immunotherapy, and combination approaches offering new hope for patients. Early detection, improved palliative care, and a continued focus on research and innovation will be crucial in further enhancing the prognosis and quality of life for those affected by this devastating disease.

Conclusion

In conclusion, the fight against lung cancer has witnessed remarkable advancements in recent years, offering renewed hope for patients and their families. The emergence of targeted therapies, the transformative impact of immunotherapy, and the synergistic potential of combination approaches have revolutionized the treatment landscape. Coupled with improvements in early detection and a growing emphasis on palliative care, these advancements have the power to significantly improve prognosis and quality of life for those affected by this devastating disease.

While challenges remain, the continued dedication of researchers, clinicians, and the medical community as a whole holds the promise of even greater strides in the future. By staying at the forefront of innovation and maintaining a steadfast commitment to providing comprehensive, patient-centered care, the fight against lung cancer with the best thoracic surgeon for lung cancer can continue to make meaningful progress, offering hope and healing to those in need.

#best thoracic surgeon in mumbai #lung surgeon in thane #thoracic surgery center

0 notes

deshmukh001 · 9 months

Text

Revolutionizing Cancer Treatment: A Comprehensive Overview of Advancements in Cancer Immunotherapy

In the ever-evolving landscape of cancer treatment, immunotherapy has emerged as a groundbreaking approach, offering new hope to patients and transforming the way we combat this complex disease. Dr. Snita Sinukumar, a distinguished Cancer Specialist in Pune, has been at the forefront of incorporating these advancements into her practice, leading the charge in providing cutting-edge care to her patients. In this article, we will delve into the remarkable strides made in cancer immunotherapy and the impact it has on patient outcomes.

Understanding Cancer Immunotherapy: A Paradigm Shift in Treatment

Traditionally, cancer treatments like chemotherapy and radiation therapy have targeted rapidly dividing cells, affecting both cancerous and healthy cells. Immunotherapy, on the other hand, harnesses the power of the body's immune system to identify and eliminate cancer cells with remarkable precision.

Key Components of Cancer Immunotherapy

1. Checkpoint Inhibitors: Unleashing the Immune System

One of the most significant breakthroughs in immunotherapy involves checkpoint inhibitors. These drugs block inhibitory checkpoints on immune cells, such as PD-1 and CTLA-4, allowing the immune system to recognize and attack cancer cells more effectively. Dr. Snita Sinukumar has successfully integrated checkpoint inhibitors into her treatment protocols, witnessing improved responses in several cancer types.

2. CAR-T Cell Therapy: Precision Targeting

CAR-T cell therapy is a personalized approach that involves modifying a patient's own T cells to express chimeric antigen receptors (CARs). These engineered cells can recognize and target specific proteins on cancer cells. Dr. Sinukumar has been a pioneer in adopting CAR-T therapy for her patients, particularly in cases where other treatments may have shown limited success.

3. Personalized Cancer Vaccines: Tailoring Treatment for Individuals

Advancements in genomic profiling have paved the way for personalized cancer vaccines. By analyzing the genetic makeup of a patient's tumor, specialists like Dr. Sinukumar can develop vaccines that stimulate the immune system to target the unique mutations present in the cancer cells. This tailored approach enhances the efficacy of the immune response.

Success Stories in Pune: Dr. Snita Sinukumar's Impact

Dr. Sinukumar's dedication to incorporating the latest advancements in cancer immunotherapy has led to remarkable success stories in Pune. Patients who once faced limited treatment options now experience extended survival and improved quality of life under her care.

Challenges and Future Directions

While the progress in cancer immunotherapy is promising, challenges remain. Some patients may not respond to immunotherapy, and there can be immune-related side effects. Ongoing research, supported by specialists like Dr. Sinukumar, aims to address these challenges and expand the applicability of immunotherapy across various cancer types.

Conclusion: A Bright Future for Cancer Treatment in Pune

In conclusion, the field of cancer immunotherapy has undergone unprecedented advancements, and Dr. Snita Sinukumar's commitment to integrating these innovations into her practice is transforming the landscape of cancer care in Pune. As we look towards the future, the collaboration between dedicated specialists and ongoing research promises even more exciting breakthroughs, bringing us closer to a world where cancer is not just treatable but conquerable. Dr. Sinukumar's tireless efforts exemplify the hope and progress that cancer immunotherapy offers to patients in their journey toward healing and recovery.

#Cancer Specialist in Pune #Surgical Oncologist in Pune #Oncologist in Pune #Women's Cancer Treatment in Pune

0 notes

poojascmi · 1 year

Text

Global Immuno-oncology Drugs Market Is Estimated To Witness High Growth Owing To Increasing Incidence of Cancer and Growing Adoption of Immune Checkpoint Inhibitors

The global Immuno-oncology Drugs Market is estimated to be valued at US$ 17,394.2 million in 2023 and is expected to exhibit a CAGR of 16.8% over the forecast period 2023-2030.

A) Market Overview:

The Immuno-oncology Drugs Market includes various drugs and therapies that utilize the body's immune system to fight cancer. These drugs work by enhancing the immune response against cancer cells, thereby improving the survival rates and quality of life for patients. Key products in the market include immune checkpoint inhibitors, immune modulators, monoclonal antibodies, and cancer vaccines. These treatments have shown promising results in treating various types of cancer, such as lung cancer, melanoma, and bladder cancer.

B) Market Dynamics:

The market is driven by two key factors: the increasing incidence of cancer and the growing adoption of immune checkpoint inhibitors. The incidence of cancer is rising globally, with lung cancer, colorectal cancer, and breast cancer being the most common types. This has led to a significant demand for effective and targeted treatments like Immuno-oncology Drugs.

Additionally, the growing adoption of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, has revolutionized cancer treatment. These drugs have shown remarkable efficacy in treating multiple types of cancer and have become a standard of care in many cases. For example, drugs like Keytruda and Opdivo have received approvals for multiple indications, including lung cancer and melanoma.

C) Market Key Trends:

One key trend in the Immuno-oncology Drugs Market is the increasing focus on combination therapies. Researchers and pharmaceutical companies are exploring the benefits of combining Immuno-oncology Drugs with other treatment modalities, such as chemotherapy, radiation therapy, and targeted therapy. Combination therapies have shown improved response rates and survival outcomes compared to single-agent therapies. For instance, the combination of Keytruda and chemotherapy has shown superior results in the treatment of lung cancer.

D) SWOT Analysis:

Strengths:

1. Increasing incidence of cancer.

2. Growing adoption of immune checkpoint inhibitors.

Weaknesses:

1. High cost of Immuno-oncology Drugs.

2. Limited patient access and affordability in developing countries.

Opportunities:

1. Advances in personalized medicine and biomarker-driven therapies.

2. Potential for expanding applications of Immuno-oncology Drugs in various cancer types.

Threats:

1. Stringent regulatory pathways for drug approvals.

2. Competition from alternative treatment modalities, such as targeted therapies.

E) Key Takeaways:

- The global Immuno-oncology Drugs Market is expected to witness high growth, exhibiting a CAGR of 16.8% over the forecast period, due to increasing incidence of cancer and growing adoption of immune checkpoint inhibitors.

- North America is expected to dominate the market, owing to the presence of key players, well-established healthcare infrastructure, and high healthcare expenditure.

- Key players operating in the global Immuno-oncology Drugs Market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG. These companies are investing in research and development, strategic collaborations, and product launches to maintain their market position.

In conclusion, the Immuno-oncology Drugs Market is poised for significant growth due to the increasing incidence of cancer and the adoption of innovative treatments like immune checkpoint inhibitors. Combination therapies and advances in personalized medicine present further opportunities for market expansion. However, challenges such as high costs and limited access in developing countries need to be addressed to ensure equitable patient care.

#Immuno-oncology Drugs Market #Immuno-oncology Drugs Market Study #Immuno-oncology Drugs Market growth #Immuno-oncology Drugs Market Analysis #Immuno-oncology Drugs Market Value #Immuno-oncology Drugs Market insights #Coherent Market Insights #Immuno-oncology Drugs

0 notes

siva621 · 1 year

Text

Immuno Oncology Market: Empowering the Body to Fight Cancer

Introduction:

The field of cancer treatment has witnessed groundbreaking advancements over the years. Among these, Immuno Oncology (IO) Market has emerged as a revolutionary approach to combat cancer. This article delves into the realm of Immuno Oncology, exploring its mechanisms, current market players, trends, growth potential, challenges, regulatory landscape, and future prospects.

Understanding Immuno Oncology:

What is Immuno Oncology?

Immuno Oncology, also known as immunotherapy, is a specialized branch of cancer treatment that harnesses the body's immune system to recognize and attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, IO stimulates the patient's immune response, helping it identify and eliminate cancer cells more effectively.

How does Immuno Oncology work?

IO treatments utilize various techniques to bolster the immune system. One of the key approaches involves using checkpoint inhibitors, which inhibit specific proteins that restrain the immune system, thereby allowing it to target cancer cells more efficiently.

The role of the immune system in cancer treatment:

The immune system plays a vital role in recognizing abnormal cells, including cancerous ones. However, cancer cells can develop strategies to evade the immune system. IO works to reverse this evasion, enabling the immune system to recognize and destroy cancer cells.

Key Players in the Immuno Oncology Market:

Pharmaceutical Companies:

Leading pharmaceutical companies have invested significantly in IO research and development. They are actively engaged in clinical trials and launching innovative IO therapies.

Biotechnology Firms:

Biotech companies are at the forefront of developing novel IO treatments. Their agility and focus on cutting-edge research have led to several promising advancements.

Research Institutions:

Academic and research institutions also play a crucial role in IO research. They contribute valuable insights and collaborate with industry players to drive progress.

Current Trends and Advancements:

Checkpoint Inhibitors:

Checkpoint inhibitors have revolutionized cancer treatment. They target specific proteins like PD-1 and CTLA-4, enhancing the immune system's ability to attack cancer cells.

CAR-T Cell Therapy:

CAR-T cell therapy involves modifying a patient's T-cells to express chimeric antigen receptors (CARs), enabling them to recognize and destroy cancer cells more effectively.

Cancer Vaccines:

Cancer vaccines are designed to stimulate the immune system to recognize and remember cancer cells, aiding in their elimination.

Adoptive Cell Transfer:

Adoptive cell transfer involves extracting, modifying, and reinfusing a patient's T-cells to boost their cancer-fighting capabilities.

Market Size and Growth Potential:

Global Immuno Oncology Market Size:

The IO market has experienced rapid growth in recent years, and it is projected to continue expanding at a substantial rate.

Factors driving market growth:

Increasing cancer prevalence, rising demand for effective and targeted therapies, and supportive government initiatives are fueling the growth of the IO market.

Future projections:

The IO market is poised for further growth, with ongoing research and development paving the way for groundbreaking treatments.

Challenges and Opportunities:

Managing Side Effects:

While IO treatments offer promising results, they can also cause immune-related side effects that need careful management.

Patient Access and Affordability:

Ensuring broad patient access to IO therapies and addressing cost concerns remain critical challenges.

Emerging Markets:

IO presents significant opportunities in emerging markets, where there is a rising demand for advanced cancer treatments.

Regulatory Landscape:

FDA Approval Process:

IO therapies undergo rigorous evaluation by regulatory authorities like the FDA to ensure safety and efficacy before approval.

Compliance and Safety:

Continuous monitoring of IO treatments is crucial to identify and address potential safety concerns.

International Regulations:

The IO market is subject to varying regulations across different countries, necessitating compliance with diverse standards.

Collaborations and Partnerships:

Industry-Academia Collaborations:

Collaborations between pharmaceutical companies and academic institutions foster innovation and knowledge exchange.

Cross-Industry Partnerships:

Partnerships between different industries can lead to innovative IO solutions and improved patient outcomes.

Future Outlook:

Innovations on the horizon:

Ongoing research holds the promise of introducing novel IO therapies with even higher efficacy.

Potential breakthroughs:

Combination therapies, personalized medicine, and targeting rare cancers are some areas that hold potential for significant breakthroughs.

Conclusion:

The Immuno Oncology market represents a transformative era in cancer treatment, where the body's own defense mechanisms are harnessed to fight the disease. With continuous advancements, collaborations, and regulatory support, the IO market is poised to offer new hope to cancer patients worldwide.

For more insights on the immuno-oncology market forecast, download a free report sample

#Immuno Oncology Market

0 notes

pharmanucleus1 · 9 months

Text

Global CTLA-4 Therapies Market - Unveiling Cutting-Edge Insights

Global CTLA-4 Therapies Market

The global CTLA-4 Therapies market is expected to reach USD 1384.4 million by 2030, at a CAGR of 7.1% during the forecast period 2022 to 2030. The modulation of cell motility and/or PI3 kinase signaling may also be other ways that CTLA-4 works. Early multiphoton microscopy investigations to observe T-cell movement in healthy lymph nodes seemed to support the "reverse-stop signalling paradigm."

Click here for full report:

https://www.pharmanucleus.com/reports/ctla-4-therapies

Market Overview

The protein receptor CTLA-4, also known as CD152 (cluster of differentiation 152) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), serves as an immunological checkpoint and suppresses immune responses. A characteristic that is especially noticeable in malignancies is the constitutive expression of CTLA-4 in regulatory T cells as opposed to the upregulation of this protein in conventional T cells following activation. When attached to CD80 or CD86 on the surface of antigen-presenting cells, it functions as an "off" switch. An inhibitory signal is sent to T cells by the immunoglobulin superfamily member CTLA-4, which is produced by activated T cells. Similar to the T-cell co-stimulatory protein CD28, CTLA-4 binds to antigen-presenting cells' CD80 and CD86, also known as B7-1 and B7-2, respectively. CTLA-4 outcompetes CD28 for its ligands because it binds CD80 and CD86 with greater avidity and affinities. T cells receive an inhibitory signal from CTLA-4 while receiving a stimulatory signal from CD28. Additionally present in regulatory T cells (Tregs), CTLA-4 is a component of their inhibitory activity. CTLA-4 expression is enhanced by T cell activation via the T cell receptor and CD28. It's still unclear how CTLA-4 affects T cells and how it does so. According to biochemical data, CTLA-4 attenuates the signal by bringing a phosphatase to the T cell receptor (TCR). Since this work was first published, it has not been supported by the literature. Recent research has revealed that CTLA-4 may work in vivo by engulfing and removing CD80 and CD86 from antigen-presenting cells' membranes, rendering them inactive for CD28 triggering.

Click here for full report:

https://www.pharmanucleus.com/reports/ctla-4-therapies

Market Dynamics

T-cell immunological activity is negatively regulated by immune checkpoints called programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). New immunotherapies for melanoma, non-small cell lung cancer, and other cancers have been developed as a result of the inhibition of these targets, which boosted immune system activation. Ipilimumab, a CTLA-4 inhibitor, is approved to treat advanced or incurable melanoma. In patients with metastatic or incurable BRAF WT melanoma, the combination of ipilimumab and nivolumab has also been authorized. Inhibiting immune responses, especially anticancer responses, play unique roles for CTLA-4.

Mutations in the CTLA4 gene, which provides instructions to cells for producing the CTLA4 protein, are the cause of CTLA4 deficiency. The immune system's activity is slowed and controlled by this protein, which acts as a brake. The CTLA4 gene is two copies per person, one from each parent. In 2014, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) discovered that individuals with only one functional copy of CTLA4 have abnormal T-cell activity, lower levels of normal, antibody-producing B cells, higher levels of autoimmune B cells, and disruption of organs by invading immune cells. The scientists came to the conclusion that a single functional copy of CTLA4 is insufficient to generate enough CTLA4 protein for a healthy immune system.

Request for free sample report”

https://www.pharmanucleus.com/request-sample/1178

While PD-1 suppresses T cells later in an immune response, largely in peripheral tissues, CTLA-4 is hypothesized to control T-cell proliferation early in the immunological response, primarily in lymph nodes. Due to the molecular distinctions between these 2 checkpoints, immuno-oncology drugs that block them may have different clinical characteristics.

Intestinal sickness, respiratory infections, autoimmune issues, swollen lymph nodes, the liver, and the spleen are just a few of the symptoms caused by the rare ailment CTLA4 deficiency, which significantly inhibits the immune system's ability to regulate itself. In 2014, NIAID researchers and their associates discovered the illness.

Segmentation Analysis:

Based on the treatment, the CTLA-4 therapies market is categorized into autoimmune conditions and immunoglobulin deficits, and others. In 2022, the autoimmune conditions and immunoglobulin deficits segment accounted for the largest share of the market, with 59% and a market revenue of 472 million. Standard treatments for autoimmune conditions and immunoglobulin deficits may be used to treat CTLA4 deficiency. The medicine CTLA-4-Ig, also known as abatacept, which mimics the action of the CTLA4 protein and lowers immunological activity, is a potential new treatment. Abatacept is used to treat autoimmune conditions like rheumatoid arthritis, but more research is needed to determine whether it is also beneficial in treating CTLA4 deficiency. Researchers from the NIAID began a small clinical trial in 2019 to examine the efficacy and safety of intravenous infusions of abatacept for restoring or enhancing blood cell counts in persons with CTLA4 deficiency. The medication abatacept, which Bristol-Myers Squibb produces, is being given to the research.

Based on the end-user, the CTLA-4 therapies market is categorized into?clinical & laboratories, hospitals, and others. In 2022, the clinics & laboratories segment accounted for the largest share of the market, with 40.1% and a market revenue of 320.8? million. The immune dysregulation syndrome that includes substantial T cell infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system, and kidneys, is present in symptomatic CTLA-4 mutant patients. Most patients suffer from enteropathy or diarrhea. Autoimmunity, lymphadenopathy, and hepatosplenomegaly are also frequent. Thrombocytopenia, hemolytic anemia, thyroiditis, type I diabetes, psoriasis, and arthritis are among the various organs that are impacted by autoimmunity. Additionally prevalent are respiratory illnesses. It's important to note that clinical manifestations and illness progression vary, with some people being severely impacted while others have minimal disease manifestation. Even within the same family, this "variable expressivity" can be noticeable and may be explained by variations in lifestyle, exposure to pathogens, treatment effectiveness, or additional genetic modifiers.

Regional Segment Analysis of the CTLA-4 Therapies Market

Asia Pacific emerged as the largest market for the global CTLA-4 Therapies market, with a market share of around 39% and 800 million of the market revenue in 2022.

Competitive Landscape

The report offers the appropriate analysis of the key organizations/companies involved within the global CTLA-4 Therapies market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the mark

#CTLA-4 Therapies Market #Global Market Trends #Latest Therapeutic Advancements #Innovations in CTLA-4 Therapies #Recent Developments in Immunotherapy #Immune Checkpoint Inhibitors #Cancer Treatment Breakthroughs

0 notes

abeomicsinc · 5 years

Text

Cancer Immunotherapy

Recent advances in treating cancer patients have resulted in the development of biological therapies that can prove to be a promising alternative to conventional cancer therapies. Immunotherapy harnesses the body’s immune system to identify and fight effectively against cancer cells. Immunotherapy works by attacking the growth of cancer cells or stimulating the immune system to kill cancer cells. Contradictory to the standard cancer treatment regimes such as chemotherapy, radiation therapy, which act on both normal and cancerous cells, immunotherapeutic treatments are highly specific. A wide range of cancer immunotherapy approaches exists such as immune checkpoint blockers, cancer vaccines, immune-modulators, monoclonal antibodies and cell based immunotherapies have demonstrated to be effective against cancer patients.

The most commonly targeted form of cancer chemotherapy is the use of monoclonal antibodies as they can be tailor-made in the laboratory. They have unique antigen specificity thereby allowing themselves to attach to specific epitopes on cancer cells. This flags the cancer cells and makes it more visible to the immune system so that it can find and destroy those cells. Currently, most of the monoclonal antibodies are undergoing phase 3 clinical trials or awaiting FDA review process. Unlike monoclonal antibodies, non-specific immunotherapy approaches such as administration of immunomodulatory cytokines are also being used to treat melanoma. Cytokines are hormones that are endogenously produced by the body to enhance or suppress T-cell response against cancer cells. IFN-α and IL-2 are most commonly characterized cytokines used in cancer immunotherapy.

The primary cell-based immunotherapy strategy which is successful these days is the use of T-cell therapy, wherein cancer T cells removed from blood are modified with chimeric antigen receptor (CAR) and is then infused back into the patients to treat metastatic cancer. Another form of cell-based immunotherapy used is tumor-infiltrating lymphocytes (TIL) therapy, wherein TIL is surgically removed from tumor tissue and is considerably increased in the laboratory by adding cytokines to it and is then reinfused back into the patient.

A promising treatment that has emerged in recent times for treatment of melanoma is the use of immune checkpoint inhibitors. They act by inhibiting the checkpoint receptors on T cells that act as brakes to the immune system thereby mediating antitumor responses. Some of the commonly used antibody inhibitors that have been commercialized are PD-1, PDL-1, and CTLA-4.

Another more focused approach to cancer immunotherapy is the use of vaccines to encourage the immune system to generate antibodies that can target tumor specific antigens, thereby eradicating cancerous cells. Cancer vaccines include peptide-based, dendritic cell-based, tumor cell-based and DNA cell based. Cancer vaccines can be broadly classified as preventive or therapeutic. Preventive vaccines are commercially available for against cervical and liver cancer causing viruses such as human papillomavirus and hepatitis B virus, respectively.

However, in spite of these advances, limitation such as tumor heterogeneity, unpredictable efficacy and identification of potential markers still exist in the field of cancer immunotherapy. Therefore, new more targeted cancer immunotherapies and preventive strategies are being developed and tested, which will deliver novel efficacious therapy against relapsed or refractory cancer patients.

ABEOMICS Inc. provides innovative, well validated research reagents to support research in the field of immune oncology. The product line includes Stable cell lines and Reporter cell lines, Antibodies, ELISA kits, Recombinant proteins as well as compound screening services for new drug molecules.

#Stable cell line Reporter Cell line Immune Check point Cancer compound screening services CTLA4 PD-L1 Antibody PD1 Antibody PD-L1 Stable Cel

1 note · View note

healthcare-market · 3 years

Text

Cancer Immunotherapy Market Report Analysis With Industry Share Published by Leading Research Firm

The increasing prevalence of cancer across the world has influenced a number of markets. An important one among those is the global cancer immunotherapy market. According to Transparency Market Research (TMR), a leading market research and intelligence firm, the opportunity in the global cancer immunotherapy market will rise at a solid CAGR of 14.60% during the period from 2016 to 2024.

Read Report Overview: https://www.transparencymarketresearch.com/cancer-immunotherapy-market.html

In terms of therapies, monoclonal antibodies have been registering the most prominent demand so far. The affordability of this therapy has given it an upper hand over other types of therapies. Its high popularity will continue to attract significant demand in the near future, keeping this segment on the top most position. On the other hand, the demand for immune checkpoint inhibitors is also expected to rise over the next few years due to its greater success rate and superior efficacy.

Cancer immunotherapy finds extensive utilization in the treatment of prostate cancer, blood cancer, melanoma, lung cancer, breast cancer, colorectal cancer, and several other chronic diseases. Among these, the demand for immunotherapy is relatively higher in the breast cancer segment. Lung cancer is also presenting a considerable increase in the rate of demand for immunotherapy. The rising population base of smokers and the alarming increase in air pollution in urban areas are the main factors behind this, states the research report.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4312

Cancer Immunotherapy Reports High Demand

All these factors are propelling the global cancer immunotherapy market. Although the future of this market looks bright, it may face challenges from strict government regulations in the near future. The absence of appropriate infrastructure for cancer diagnosis and screening in emerging nations is also expected to hinder this market in the years to come, reports the research study.

Request for Analysis of COVID19 Impact on Cancer Immunotherapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=4312

Europe and North America to continue to Lead

Geographically, the worldwide cancer immunotherapy market is segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Europe and North America have been leading this market since long. The presence of superior medical and healthcare infrastructure is supporting both the regional markets. The ongoing research activities for the development of innovative therapies for cancer treatment are likely to aid these markets in the coming years, resulting in their continued dominance. With ample of untapped opportunities, Asia Pacific is also expected to report a promising growth in the near future, notes the market study.

Buy now Cancer Immunotherapy Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=4312&ltype=S

The leading players in the global cancer immunotherapy market are Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Co., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Sanofi, Merck & Co. Inc., Janssen Biotech Inc., Pfizer Inc., Novartis AG, Spectrum Pharmaceuticals Inc., and Takeda Pharmaceuticals.

The review is based on a report by Transparency Market Research, titled “Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC’s (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/numerous-players-in-ultrasound-gels-market-lean-on-innovation-in-formulation-for-surgical-lubricant-gels-acceptance-of-silicon-solutions-in-medical-devices-spurs-prospects-tmr-301266741.html

https://www.prnewswire.com/news-releases/projected-rise-of-prevalence-of-osteoporosis-in-numerous-regions-drive-demand-for-new-treatment-options-for-osteoporosis-drugs-market-tmr-301271544.html

https://www.prnewswire.com/news-releases/new-engineering-approaches-in-vascular-grafts-market-expands-horizon-of-endovascular-surgeries-synthetic-products-attract-rd-tmr-301278115.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

0 notes

mukongs · 3 years

Text

The soluble tumors bacteria YB1 has pioneered new methods of cancer immunotherapy, and can it pry the market by hundreds of billions of dollars in the future?

The development of life science and technology has completely subverted the social life and medical and health system of human beings in the past hundred years, and the quality of human life has been greatly improved, while completely tackling cancer, a disease that has long plagued human health, has become the common goal of the global medical and scientific community.

In recent decades, the global field of cancer treatment has developed rapidly, and mainstream treatments have evolved from traditional methods such as surgery, radiotherapy and chemotherapy to tumor-targeted therapy and, more recently, tumor immunotherapy, which are better at improving patient outcomes while reducing systemic adverse reactions in patients in treatment. Compared with traditional tumor treatments, targeted therapy and immunotherapy benefit patients in improving efficacy, reducing symptoms or improving quality of life by targeting specific cancer-causing pathways and utilizing the patient's immune system.

Overview of the global and Chinese cancer treatment industry

Currently, the global and Chinese cancer drug market consists of chemotherapy, targeted therapy and immunotherapy. Globally, targeted therapies and immunotherapy account for 83.8% of the global cancer treatment market and are expected to grow to 89.8% by 2030, according to public data reported?

In the Chinese market, targeted therapies and immunotherapy in the field of cancer treatment have greater potential for growth, driven by favorable policies, increasing patient spending power and the introduction of more innovative therapies in China, with the total contribution expected to increase from 36.6% in 2020 to 85.8% in 2030.

Although targeted therapies and immunotherapy approaches are inherently different, in many cases it has been shown that a combination of the two therapies creates synergies, usually one that complements the other, releasing the patient's anti-tumor immunity and thus improving efficacy. This combination has been improved through professional exploration to produce better results in clinical practice and has been shown to be a promising new treatment strategy in the field of cancer treatment.

Oncology immunotherapy will hit the $100 billion Blue Sea market

Tumor immunotherapy has gradually established itself as a pillar in the global field of cancer treatment in recent years, designed to stimulate the patient's own immune system to produce or enhance an anti-tumor immune response to control or eradicate cancer cells.

The discovery and development of cancer immunotherapy in recent years has marked a milestone in cancer treatment and will be an important boost to the growth of the global cancer drug market, as it provides lasting relief and is often well tolerated in several patients with advanced cancer. It is worth mentioning that because tumor immunotherapy works through the patient's own immune system, immunotherapy has fewer side effects than traditional cancer treatments such as chemotherapy and radiotherapy.

The global market for oncology immunotherapy has increased from $9.6 billion in 2016 to $35.1 billion in 2020 and is expected to reach $108.2 billion by 2025, according to the institute's professional report The global cancer immunotherapy market will reach US$229.8 billion over 30 years, with CAGR of 25.3% and 16.3% from 2020 to 2025 and 2025 to 2030, respectively. For the foreseeable future, cancer immunotherapy will usher in hundreds of billions of dollars of blue sea market.

In 2020, oncology immunotherapy accounts for 23.4% of the global cancer drug market, and by 2030 it is expected to account for approximately 47.6% of the global oncology market.

On the domestic market, China's oncology immunotherapy market has reached RMB14.8 billion in 2020 and is expected to grow to RMB88.9 billion by 2025 and further to RMB272.8 billion by 2030, with CAGR of 66.8% and 16.4% from 2019 to 2024 and 2024 to 2030, respectively.

According to the data, oncology immunotherapy will account for 7.5% of China's total cancer drug market revenue in 2020 and is expected to continue growing in the future, accounting for about 39.9% of China's cancer market by 2030.

Will the innovative therapies take advantage of corner overtaking? Tumor immunotherapy shapes the development of new logic

In the face of the growing $100 billion Blue Sea market in the next five years, it is even more important to clarify the path of development in the field of oncology immunotherapy at this stage and in the future, and the choice and layout of the segmented track is about how much market share industry participants can ultimately capture.

After years of evolving cancer treatment paradigms, the development of oncology immunotherapy is now playing an increasingly essential role, subdivision circuits continue to spawn new therapies, by improving the effectiveness of treatment of various types of cancer, to begin to provide cancer patients around the world with more valuable treatment options.

The early stages of the development of global tumor immunotherapy, mainly characterized by immuno-checkpoint inhibitors single therapy, including PD-1/L1 inhibitors and CTLA-4 inhibitors, in a variety of tumors to achieve about 20% ORR, replacing chemotherapy as the treatment standard for a variety of cancer indications. Current mainstream immuno-tumor therapies are characterized by the combination of immuno-checkpoint inhibitors (as cornerstone drugs) with a second immuno-checkpoint inhibitor or different types of cancer therapies (e.g. chemotherapy or angiogenesis inhibitors) with an ORR (objective remission rate) of approximately 40 percent.

Hematoma viral therapy is a new tumor immunotherapy, which, in addition to checkpoint suppression, uses several viruses to selectively replicate and kill tumors directly in tumors, as well as the ability to induce effective, patient-specific anti-tumor immune response. This soluble virus has the potential to produce an immune response to specific tumor antigen groups in individual patients, including new antigens that are uniquely present in tumors.

In recent years, hemovores therapy has become a promising anti-cancer therapy. The soluble virus, which destroys cancer cells without damaging normal tissue through tumor-specific replication, then promotes congenital and adaptive immune responses, demonstrating great potential for cancer treatment. The emergence of germ therapy for Soloma may pry into the larger market of the future.

Hemolytic bacterial therapy is currently more cutting-edge than the tumor virus of the emerging cancer immunotherapy program, because most of the tumors in the human body (more than 90%) will form solid tumors, and solid tumor microenvironment has a significant characteristic, that is, in the center of the tumor will form a very special low oxygen region, this low oxygen region is significantly different from normal human tissue, so the physical tumor oxygen-deficient microenvironment has become an ideal target for tumor target therapy.

The emergence of germ therapy for Hemolytic may pry into the larger market of the future

As an anaerobic or axial anaerobic microorganism, the anaerobic region of the tumor provides an ideal place for survival - the tumor bacteria is a large class of invasive intracellular bacteria, the reaction between this type of microorganism and the host is mediated by the type III secretion mechanism, which can transmit the expression of the effect gene at the same time express a variety of therapeutic properties of proteins, therefore, detoxifying tumor bacteria is a more ideal therapeutic drug carrier.

In 2011, the core research and development team of HKND YB1 PHARMACEUTUCAL LIMITED. realized the efficient programming technology of salmonella Lambda-RED for the first time in the experiment, established the basis of salmonella synthetic biology transformation, and solved the biosecurity risk in the research and development of bacterial therapy. After establishing the basis for the synthetic biology transformation of salmonella, the company successfully invented a genetically engineered strain of salmonella YB1, a genetically engineered strain of salmonella typhoid, which is also the world's first synthetic biology technology to transform the invention of the tumor bacterial carrier products.

In 2021’s May, YB1 technology-related machine theory was published in Nature Communications, a leading international journal, and studies showed that the safety and efficacy of the synthesis bacterial product had been verified. Thus, with the successful launch of the oncolytic bacterial carriers YB1, bacterial therapy ushered in a new era of development, the clinical application of the hemolytic bacteria is within reach, in the future, can it pry a significant share of the industry market? Believe that time will tell.

0 notes

sandlerresearch · 3 years

Text

Melanoma - Global Drug Forecast and Market Analysis to 2029 published on

https://www.sandlerresearch.org/melanoma-global-drug-forecast-and-market-analysis-to-2029.html

Melanoma - Global Drug Forecast and Market Analysis to 2029

Melanoma – Global Drug Forecast and Market Analysis to 2029

Summary

Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic melanoma is treated with systemic therapy with either PD-1 monotherapy (Opdivo or Keytruda) or BMS’ combination therapy of Opdivo + CTLA-4 inhibitor Yervoy. BRAF V600-positive patients also have the option of receiving targeted therapy.

The global market is expected to grow from $5.6B in 2019 to $7.46B in 2029 at a CAGR of 2.9%. The introduction of 12 new pipeline agents as well as label expansions of currently approved agents are key drivers of this market growth. However, multiple patent expiries of market-leading brands, occurring across the 8MM, will prohibit growth.

Key Highlights

– The main drivers of growth include the anticipated approval and launch of 12 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period. – The main barriers to growth in the 8MM are key patent expiries of immune checkpoint inhibitors and targeted BRAF/MEK inhibitors – Among the late-stage pipeline products and marketed agents, immune checkpoint inhibitors are expected to generate the greatest revenues over the forecast period. – The most important unmet needs in the melanoma market include: wider therapeutic options for patients who progress on immune checkpoint inhibitors, effective treatment for patients with brain metastases, biomarkers to guide treatment decisions, and wider options for patients with acquired resistance to targeted therapy.

KEY QUESTIONS ANSWERED

– 12 late-stage pipeline agents are expected to enter the melanoma market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why? – What are the current unmet needs melanoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D? – What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions. – What are the main corporate trends? Who are the current and future players?

Scope

– Overview of melanoma including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. – Topline melanoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period. – Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting melanoma therapeutics sales in the 8MM. – Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III). – Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track drug sales in the global melanoma therapeutics market from 2019-2029. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

#Pharmaceutical

0 notes